Biomarkers and Diagnostics

What to measure, how often, what the targets are, and how to act on a result — from at-home blood panels to clinic-level imaging (CAC, CCTA, full-body MRI, MCED). The ‘measure twice, intervene once’ chapter.

Start with ApoB Screening: a particle-count view of atherogenic lipoprotein risk that explains why LDL-C alone can miss discordance. Resting Heart Rate and HRV adds the wearable-era autonomic signal: useful for trends, weak as a daily verdict. The adjacent entries separate inherited lipid risk, annual bloodwork, glucose exposure, body composition, imaging, and biological-age testing. The section’s practical question is not how much data can be gathered, but which measurements change risk interpretation without creating testing theater.

Read straight through, or land on a specific entry and follow its outgoing links into the rest of the book.